FDA approves Schering-Plough's Pegintron to treat paediatric hepatitis C
This article was originally published in Scrip
The US FDA has granted Schering-Plough's combination therapy of Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) marketing approval for use in previously untreated patients three years and older with chronic hepatitis C (HCV).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.